Overview of Vicks Acta Plus

Property	Description
Active ingredients	Carbetapentane Citrate, Guaifenesin, Cetylpyridinium Chloride
Form	Syrup or Oral Solution
Pharmacological class	Non-opioid Antitussive, Expectorant, Antiseptic
Common use	Symptomatic relief of wet and dry cough
Origin	Synthetic combination product

Vicks Acta Plus is defined as an upper respiratory combination product formulated as an oral solution or syrup for the symptomatic management of cough. This medicine is a combination drug because it integrates multiple synthetic active ingredients from distinct pharmacological classes to address complex cough symptoms. It is taken via the oral route of administration to provide relief from irritative cough and associated congestion.

Composition: A Combination of Antitussive, Expectorant, and Antiseptic Agents

The formula contains the key active ingredients Carbetapentane Citrate (also known as Pentoxyverine Citrate), Guaifenesin, and Cetylpyridinium Chloride. Carbetapentane is categorized as a non-opioid antitussive agent, designed to suppress the central cough reflex. Its complementary ingredient, Guaifenesin, functions as an expectorant, a distinct pharmacological class that aids in thinning mucus by increasing the volume and reducing the viscosity of bronchial secretions. Guaifenesin is used for relieving chest congestion and cough symptoms. Additionally, Cetylpyridinium Chloride, a quaternary ammonium salt, provides localized antiseptic activity within the mouth and throat, offering mild soothing relief.

General Purpose: Relieving Both Wet and Dry Cough Symptoms

The general purpose of Vicks Acta Plus is to provide relief for a broad spectrum of cough symptoms resulting from colds or bronchial irritations. The formula is uniquely equipped to manage the irritating, persistent dry, non-productive cough through the cough-suppressant action of Carbetapentane. Concurrently, the mucus thinning properties of Guaifenesin assist the body in clearing wet, productive coughs associated with chest congestion, ultimately providing targeted symptomatic management for various cough presentations within one preparation.

Regulatory References

MedlinePlus - Guaifenesin

What side effects are possible with Vicks Acta Plus?

Possible Side Effects and Safety Information

The safety profile for Vicks Acta Plus is defined by the officially documented adverse reactions associated with its active components: Carbetapentane Citrate, Guaifenesin, and Cetylpyridinium Chloride. Regulatory documents categorize possible adverse reactions based on their frequency and the body system affected.

Adverse effects are primarily reported in two system-organ classes:

Nervous System Disorders: Reactions commonly reported include drowsiness, dizziness, and headache. Less common effects may include confusion, tremors, or feelings of nervousness, as noted in regulatory texts for similar formulations.
Gastrointestinal Disorders: Common effects involving the digestive tract include nausea, vomiting, stomach upset, and diarrhea, which are frequently associated with the expectorant component.

Serious Reactions and Regulatory Restrictions

Official labeling documents emphasize the potential for serious allergic reactions (hypersensitivity), including symptoms such as swelling of the face, lips, or tongue, or the presence of hives. These reactions are rare but require immediate attention.

Safety constraints and limitations are also documented in official prescribing information:

Driving and Alertness: Due to the risk of drowsiness or dizziness, caution is advised regarding activities that require mental alertness, such as driving or operating machinery.
Drug Interactions: The medicine is contraindicated for use at the same time as, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI). This is a critical safety restriction documented in the label.
Special Populations: Caution is typically advised in individuals with certain pre-existing conditions such as heart disease, high blood pressure, glaucoma, or diabetes, as noted in official regulatory texts.

Overdose and Emergency Response

The official regulatory profile for an overdose of Vicks Acta Plus (containing Carbetapentane Citrate, Guaifenesin, and Cetylpyridinium Chloride) is defined by the potential systemic effects of its active ingredients, necessitating immediate emergency action.

Overdose Scope

Property	Official Regulatory Statement
Documented Overdose Presentations	Symptoms include CNS effects such as somnolence, agitation, and excitability, alongside gastrointestinal distress like nausea and vomiting. Anticholinergic effects such as dry mouth and tachycardia are also documented.
Physiological Systems Affected	Central Nervous System (CNS), Respiratory System, Cardiovascular System, and Gastrointestinal System.
Dose-related or Exposure-related Factors	Pediatric patients are noted to be at an increased risk of severe CNS effects. Prolonged, excessive use of Guaifenesin is associated with the risk of nephrolithiasis (kidney stones).
When Immediate Medical Help is Required	Regulatory guidance mandates to seek immediate medical attention for all suspected overdoses. Urgent help is required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened (as per label-derived instructions).

Resulting Overdose Structure

The regulatory stance mandates immediate contact with a Poison Control Centre or emergency services due to the potential for overdose to progress to severe CNS depression and life-threatening outcomes such as respiratory depression and coma. Management is strictly defined as symptomatic and supportive treatment; no specific antidote is known for the primary antitussive agent. Hospital monitoring may include ECG monitoring and continuous observation of vital and neurological status.

Therapeutic Uses of Vicks Acta Plus

Vicks Acta Plus is commonly used across therapeutic domains where short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden. It is applied when multiple symptoms occur together, creating noticeable physiological strain, often associated with conditions characterized by periods of heightened symptoms such as the common cold or flu. The medication's antitussive component is used to relieve cough caused by the common cold, flu, and bronchitis.

Managing Dual-Natured Cough Symptoms

This preparation is relevant when symptoms cluster into the disruptive pattern of a dual-natured cough, managing both the dry, irritative cough that interferes with comfort and the wet, productive cough linked to secretions. The therapeutic benefit centers on providing support that helps reduce the frequency and intensity of coughing episodes, which may assist with maintaining functional stability when symptoms interfere with daily functioning or rest.

Addressing Chest Congestion and Phlegm Clearance

Vicks Acta Plus is applied in contexts where patients need assistance with chest congestion and excessive mucus. This domain of use focuses on supportive therapeutic benefit by aiding in the thinning and loosening of thick phlegm. This action contributes to easier airway clearance and helps patients cope more steadily with the burden of respiratory secretions.

Easing Throat and Respiratory Irritation

The medication is commonly used across conditions presenting with acute episodes to help with symptoms related to inflammatory or irritative states in the throat. Applied across domains where additional symptomatic support is needed, it offers a localized, soothing benefit. This supportive relief helps improve day-to-day comfort during symptomatic periods by easing the distress caused by minor throat irritation.

The common therapeutic uses of Vicks Acta Plus include assisting with symptomatic relief for coughs associated with the common cold, influenza, bronchitis, and general upper respiratory tract irritations.

“The combination of cough suppression and mucus management provides integrated symptomatic relief when cold symptoms are most disruptive.”

Quick Fact: Relief for Dual Symptoms
Primary Focus: Simultaneous management of both dry, irritative cough and wet, productive cough.
Core Benefit: Provides supportive relief that helps ease the overall symptom burden and assists with maintaining functional stability.

Eligibility and Restrictions for Use

The official regulatory profile for Vicks Acta Plus establishes clear boundaries for patient eligibility based strictly on age, specific medical conditions, and physiological status. Eligibility is classified into populations for standard use, restricted use, and absolute contraindication.

Populations Who Must Not Use the Medicine (Contraindicated)

Use of Vicks Acta Plus is formally prohibited for individuals with a known hypersensitivity to any of its components. Official labeling dictates that the product is contraindicated in patients with pre-existing conditions such as Epilepsy, Asthma, a persistent or chronic cough, or other chronic lung diseases.

Age- and Condition-Based Restrictions

Adults and children ge 12 years of age are eligible for standard use. However, the medicine must not be used in children under 6 years of age. Children aged 6 to 11 years should not consume the medicine without medical advice.

Due to the need for specific medical oversight, the medicine should not be used by women during pregnancy or lactation without medical consultation. Caution is also advised for use in older adults and individuals with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Vicks Acta Plus based on government regulatory labeling. The combination of active ingredients, Carbetapentane Citrate (antitussive) and Guaifenesin (expectorant), determines the specific administration constraints.

Formal Contraindications and Timing Rules

The co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) is defined as a formal contraindication in regulatory documents. Due to the action of the antitussive component, a high-risk pharmacodynamic interaction is documented. This restriction necessitates a mandatory separation period of 14 days between stopping MAOI therapy and the initiation of this medicine.

Pharmacodynamic Interaction Risks

Concurrent use with other Central Nervous System (CNS) depressants may result in additive CNS depressant effects. This pharmacodynamic reinforcement applies to categories including certain anxiolytics, anticonvulsants, and sedating antidepressants, establishing a significant constraint when combining these medicinal products. Similarly, consumption of alcohol (ethanol) is documented as a substance that may lead to additive CNS depression when taken with this medicine. Furthermore, co-administration with other antitussive medicines is restricted. This restriction stems from a documented pharmacodynamic conflict where the cough suppression may inhibit the necessary mucus-clearing action promoted by Guaifenesin, raising the risk of bronchial secretion accumulation.

Administration Constraints

Regulatory documentation confirms that the absorption of the Guaifenesin component is unaffected by food. Therefore, there are no administration constraints requiring dose separation from meals.

Mechanism of Action

Vicks Acta Plus is formulated with three distinct compounds that target different biological receptors and pathways to achieve its intended physiological effects.

Dextromethorphan (DXM): Central Action

Dextromethorphan acts centrally by agonizing the sigma1 and mu-opioid receptors located within the medullary cough center. This receptor interaction modulates efferent signaling from the brainstem to the respiratory muscles, initiating a mechanistic cascade to alter the cough reflex pathway.

Pseudoephedrine: Adrenergic Receptor Agonism

Pseudoephedrine is classified as a sympathomimetic amine. It functions as a non-selective alpha and beta-adrenergic receptor agonist on vascular smooth muscle cells. This agonism induces vasoconstriction in the nasal mucosal vasculature, which is the system-level physiological consequence of its mechanistic activity.

Guaifenesin: Secretion Rheology Modulation

Guaifenesin alters the rheology (flow properties) of respiratory secretions. Its molecular action is associated with increasing the volume of fluid content within the secretions while simultaneously decreasing their overall viscosity. This change in fluid dynamics acts as a pathway modulation to facilitate the inherent process of mucociliary transport.

Dosage and Administration Information

The administration of Vicks Acta Plus, a synthetic combination cough medicine, follows established protocols for its active components. The medicine is strictly intended for oral consumption only and its use is limited to short-term, symptomatic management.

Official Dosing and Frequency

The standard dose for adults and adolescents (12 years and over) typically ranges from 5 mL to 10 mL of the oral solution per single administration. Dosing frequency is as needed, with a required interval of 4 to 6 hours between administrations. Use must not exceed a maximum of four doses in any 24-hour period to adhere to safety constraints. The overall duration of use is constrained, as the product is generally not recommended for more than five days of consecutive treatment.

Procedural Administration Details

Procedural Instruction	Official Guideline
Measurement & Preparation	The dose must be accurately measured using a specially marked measuring device, and the bottle should be shaken well before dispensing.
Timing & Fluids	The solution may be taken with or without food. Patients are encouraged to increase fluid intake (e.g., water) to support the expectorant action of Guaifenesin.
Pediatric Use	Children aged 6 to 11 years require a reduced dose, typically 5 mL. The product is not recommended for use in children under 6 years of age.
Missed Dose	If a scheduled dose is missed, the user should take the next dose when due and must not double the dose to compensate.

This established protocol dictates the precise use of the medicine, strictly defining the oral route, the required use of a measuring device for precision, and the mandatory time and frequency limits. This structured administration confirms the medicine’s role as a temporary, symptom-based intervention in accordance with official labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vicks Acta Plus

The research overview for Vicks Acta Plus, a product containing Carbetapentane Citrate, Guaifenesin, and Cetylpyridinium Chloride, is largely based on studies for the individual active components. This summary details the types of research conducted, what they examined, and where evidence remains limited, without providing clinical advice.

Evidence for Managing Acute Cough Frequency and Intensity

Research has explored the antitussive component, Carbetapentane Citrate, using short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring the natural course of symptoms over time in adults and young people with conditions associated with acute or disruptive episodes, such as the common cold. The studies monitored patient-reported outcomes describing perceived discomfort by measuring cough frequency and intensity over defined time intervals, typically lasting only a few days.

Patterns related to symptom measures were observed in some studies when compared to placebo. However, systematic reviews often highlight that findings were mixed across different trials. Evidence quality varies across studies and the consistency of findings is mixed for over-the-counter antitussives, in general. Research focuses on short-term symptom patterns; certainty remains low for the conclusive performance of this class of medicines in all patients.

Evidence for Assisting with Chest Congestion and Mucus Clearance

The expectorant component, Guaifenesin, was evaluated in research exploring the natural course of symptoms over time for conditions involving periods of heightened symptoms related to respiratory congestion. The studies monitored patient-reported outcomes regarding perceived discomfort by examining measures related to mucus characteristics, such as thickness, and patient-reported outcomes related to chest congestion severity.

The studies describe that when this ingredient was observed in some settings, patterns were noted related to measures of mucus characteristics and patient-reported assessments with expectoration. However, evidence is limited, as the findings related to Guaifenesin's effect on objective outcomes like mucus viscosity was observed in some studies but were not uniformly consistent across all published trials. The outcomes reported were often associated with single-ingredient Guaifenesin.

Key Limitations and Areas of Scientific Uncertainty

A key research limitation is that data for the specific three-ingredient preparation of Carbetapentane Citrate, Guaifenesin, and Cetylpyridinium Chloride are still emerging, meaning most available research focuses on the ingredients individually or in dual combinations. This limits the ability of research to fully characterize the combined action of the specific three-ingredient preparation. Additionally, research is often short-term, and data for certain groups remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vicks Acta Plus (FAQ)

Q: Is Vicks Acta Plus the same as other Vicks cough syrups?

A: According to the official product information, this medicine is defined by its specific combination of three active components: the antitussive Carbetapentane Citrate, the expectorant Guaifenesin, and the antiseptic Cetylpyridinium Chloride. Other cough syrups, even those marketed by Vicks, may contain different active ingredients or dosages. This specific formulation is designed to address both wet and dry cough symptoms.

Q: How long does the effect of one use of Vicks Acta Plus usually last?

A: The product labeling and administration guidelines require a period of 4 to 6 hours between administrations. This time interval is established in the product label as the minimum period that should pass between administrations to maintain safety and efficacy.

Q: Does Vicks Acta Plus help with nasal congestion as well as cough?

A: The product is primarily formulated to manage both wet and dry cough symptoms, with an emphasis on addressing symptoms related to chest congestion through the expectorant ingredient. Based on the officially listed components, the product's primary classification is not that of a nasal decongestant.

Q: Can Vicks Acta Plus be taken if I am currently using antidepressants?

A: Regulatory documents contain formal warnings regarding interactions with certain antidepressants. Regulatory warnings indicate that the medicine should not be used by individuals taking Monoamine Oxidase Inhibitors (MAOIs), and a separation period of 14 days is required. Additionally, caution is advised when using it alongside antidepressants classified as Central Nervous System (CNS) depressants due to the potential for additive effects.

Q: Does Vicks Acta Plus contain any stimulant ingredients?

A: Official product labeling classifies the active ingredients as a non-opioid antitussive, an expectorant, and an antiseptic. In their official classification, none of these specific components—Carbetapentane Citrate, Guaifenesin, or Cetylpyridinium Chloride—are typically defined as systemic central nervous system stimulants.

Q: Is it normal if Vicks Acta Plus doesn't stop my cough right away?

A: The medicine is intended for the symptomatic management of cough. Research indicates that the consistency of findings related to the antitussive effects can be mixed, suggesting results may vary among individuals. Complete cessation of symptoms may not be immediate or universally complete for every user.

Q: Does Vicks Acta Plus contain alcohol?

A: The full formulation of the medicine, including all inactive ingredients (excipients), is detailed in official regulatory labeling. This detailed product information, required by regulatory bodies, specifies whether excipients such as alcohol are present in the final product.

Q: How long does it typically take to feel the effects of Vicks Acta Plus?

A: Studies examining the pharmacokinetics of the expectorant component, Guaifenesin, indicate it reaches its maximum concentration in the blood in research settings in approximately 25 minutes. This time period indicates when the concentration of the expectorant component is typically highest in the blood.

Q: Is Vicks Acta Plus available over the counter, or do I need a prescription?

A: The active ingredients are often classified under official non-prescription, or Over-The-Counter (OTC), monographs in several regulatory regions. The specific legal status of the product (such as Over-The-Counter or pharmacy-only) is officially assigned by the national regulatory authority in each market.

Q: Can Vicks Acta Plus be taken with pain relievers like paracetamol or ibuprofen?

A: Official documentation for the active component, Guaifenesin, does not list formal interaction warnings with common pain relievers such as paracetamol (acetaminophen) or ibuprofen. This information is based on the single-ingredient profile, and users should always confirm product details on the specific package insert.

Q: Is Vicks Acta Plus free of common allergens like gluten or lactose?

A: Regulatory agencies require that the full product labeling list the presence or absence of specific inactive ingredients, known as excipients. This necessary information is listed in the full product label for review by individuals with known allergies.

Q: What are the specific legal restrictions on who can purchase Vicks Acta Plus in certain regions?

A: The specific purchase restrictions, which may include age limits or limits on the maximum quantities that can be bought per transaction, are legally defined and enforced by the specific regulatory agency or government body in the market where the product is sold.

Q: What is the safety classification of Vicks Acta Plus in major countries like the US or UK?

A: The official safety classification, such as being designated as an Over-The-Counter (OTC) or a pharmacy-only medicine, is formally assigned by the national regulatory authority. This classification is based on the specific formulation, ingredients, and dosages.

Q: Can Vicks Acta Plus affect the results of any common medical tests?

A: Official regulatory documents have noted that Guaifenesin, one of the active ingredients, may interfere with the results of certain laboratory tests. This interference is specifically documented for tests that measure urinary levels of substances like 5-HIAA and VMA.

Q: Is Vicks Acta Plus suitable for people who are sensitive to caffeine?

A: Official product information lists all ingredients. The regulatory classification confirms the product does not contain caffeine as an active ingredient, and its components are not typically defined as systemic central nervous system stimulants.

Q: What is meant by the term 'contraindication' on the Vicks Acta Plus label?

A: The term contraindication is defined in official regulatory documents as a condition or circumstance where the medicine must not be used. This restriction indicates a circumstance where the risk of harm or serious adverse effect is determined to be unacceptable.

Q: What official documents describe Vicks Acta Plus's safety profile?

A: The comprehensive safety profile, which includes all mandatory adverse reactions, warnings, and restrictions, is officially documented by the governing regulatory bodies. This information is found in documents such as the Summary of Product Characteristics (SmPC) in the EU or the Prescribing Information/DailyMed label in the US.

Q: Is the flavor of Vicks Acta Plus artificial or natural?

A: The detailed inactive ingredient list, required in the regulatory labeling, provides information regarding the composition of the product's flavor. This documentation specifies the nature of the flavoring agents used, classifying them as either originating from natural sources or being artificially derived.

How should Vicks Acta Plus be stored and disposed of?

How to Store and Dispose of Vicks Acta Plus?

The storage and disposal of Vicks Acta Plus oral solution must adhere strictly to official regulatory guidelines to maintain its stability and ensure environmental safety. This information is derived from government-approved labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C.
Protection	Keep tightly closed in the original container and protect from light and moisture.
Prohibited	Do not refrigerate and do not freeze the solution.
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Vicks Acta Plus should not be disposed of in household trash or down drains/toilets.

Regulatory protocols mandate that the medicine be returned to a pharmacist or an authorized collection point for proper disposal.

Vicks Acta Plus